Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged ≥60 Years

J Infect Dis. 2016 Jun 15;213(12):1872-5. doi: 10.1093/infdis/jiw047. Epub 2016 Feb 9.


Understanding long-term effectiveness of herpes zoster (HZ) vaccine is critical for determining vaccine policy. 176 078 members of Kaiser Permanente ≥60 years vaccinated with HZ vaccine and three matched unvaccinated members were included. Hazard ratios and 95% confidence intervals (CIs) associated with vaccination at each year following vaccination were estimated by Cox regression model. The effectiveness of HZ vaccine decreased from 68.7% (95% CI, 66.3%-70.9%) in the first year to 4.2% (95% CI, -24.0% to 25.9%) in the eighth year. This rapid decline in effectiveness of HZ vaccine suggests that a revaccination strategy may be needed, if feasible.

Keywords: adult vaccination; herpes zoster; shingles; varicella zoster virus.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Aged
  • Herpes Zoster / immunology*
  • Herpes Zoster Vaccine / immunology*
  • Humans
  • Immunization, Secondary
  • Middle Aged
  • Policy Making*
  • Proportional Hazards Models
  • Treatment Outcome
  • Vaccination


  • Herpes Zoster Vaccine